Streptozocin (Zanosar) Oncology Medication Facing Ongoing Supply Shortage

What’s in Shortage

Streptozocin Powder, For Solution (Brand name: Zanosar) is currently in shortage. This medication is classified under the therapeutic category of Oncology. The shortage affects the 100 mg/1 mL presentation (NDC 0703-4636-01).

Which Manufacturers Are Affected

Currently, Teva Pharmaceuticals USA, Inc. is the manufacturer listed with availability issues:

• Status: Unavailable
• Presentation: Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)
• Estimated Recovery: To Be Determined (TBD)
• Contact Information: 800-545-8800

Why There’s a Shortage

The reason for the shortage provided to the FDA is listed as “Other.” No specific details regarding manufacturing delays or supply chain issues were disclosed.

What Patients Should Do

Patients who are currently prescribed Streptozocin for oncology treatment should take the following steps:

1. Consult Your Healthcare Provider: Speak with your oncologist or primary physician immediately to discuss your treatment plan and potential alternatives.
2. Contact Your Pharmacist: Check with your pharmacy regarding their current stock and potential lead times for new shipments.
3. Contact the Manufacturer: You may reach out to Teva Pharmaceuticals at 800-545-8800 for the most recent updates on their supply status.

Disclaimer: Patients should consult their healthcare provider for all medical advice, diagnosis, and treatment options. Do not make changes to your medication regimen without professional medical guidance.

Source

Information provided by the FDA Drug Shortage Database.

• Initial Posting Date: 07/12/2022
• Last Updated: 02/02/2026